Zacks Research Issues Positive Outlook for Cencora Earnings

Cencora, Inc. (NYSE:COR) – Equities research analysts at Zacks Research lifted their Q1 2025 EPS estimates for shares of Cencora in a report issued on Wednesday, November 27th. Zacks Research analyst I. Bandyopadhyay now expects that the company will post earnings per share of $3.42 for the quarter, up from their prior forecast of $3.28. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Zacks Research also issued estimates for Cencora’s Q2 2025 earnings at $4.11 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.82 EPS, Q3 2026 earnings at $3.85 EPS, Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $16.17 EPS and FY2027 earnings at $17.41 EPS.

Other analysts have also recently issued reports about the stock. UBS Group lifted their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Leerink Partners decreased their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Evercore ISI lifted their target price on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, Robert W. Baird lifted their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $271.20.

Cencora Stock Up 0.1 %

COR stock opened at $250.05 on Monday. The stock has a market capitalization of $49.27 billion, a P/E ratio of 33.30, a PEG ratio of 1.66 and a beta of 0.45. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora has a one year low of $195.83 and a one year high of $253.27. The company has a 50 day moving average price of $235.84 and a two-hundred day moving average price of $233.00.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is currently 29.29%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 93,018 shares of company stock worth $22,478,942 in the last quarter. 15.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Several hedge funds and other institutional investors have recently modified their holdings of COR. Pacer Advisors Inc. increased its position in shares of Cencora by 6,855.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock worth $464,874,000 after purchasing an additional 2,035,679 shares during the last quarter. Bank of Montreal Can grew its position in shares of Cencora by 136.8% during the 2nd quarter. Bank of Montreal Can now owns 641,887 shares of the company’s stock valued at $153,623,000 after buying an additional 370,841 shares during the last quarter. American Century Companies Inc. grew its position in shares of Cencora by 155.0% during the 2nd quarter. American Century Companies Inc. now owns 598,438 shares of the company’s stock valued at $134,828,000 after buying an additional 363,796 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Cencora by 7.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock valued at $1,168,927,000 after buying an additional 338,452 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in shares of Cencora by 21.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company’s stock valued at $368,771,000 after buying an additional 292,600 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.